China Regenerative Medicine International Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was HKD 69.49 million compared to HKD 41.54 million a year ago. Net loss was HKD 107.7 million compared to net income of HKD 4.56 million a year ago.

Basic loss per share from continuing operations was HKD 0.376 compared to basic earnings per share from continuing operations of HKD 0.016 a year ago.